Femtobiomed (327610) has 14 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩36M ($25K) in reported transaction value. The earliest filing StockDrifts holds for Femtobiomed is dated 2021-07-27; the most recent is 2025-11-05. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -81.83%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2025-11-05 | BUY | 장외매수 | 이상현 Sanghyun Lee | CEO | 20.7K | ₩2,045 | -48.9% | ₩42M ($29K) |
| 2025-06-17 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 334 | ₩5,380 | -80.6% | ₩2M ($1K) |
| 2025-06-16 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 100 | ₩5,780 | -81.9% | ₩578K ($401) |
| 2025-06-13 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 200 | ₩5,690 | -81.6% | ₩1M ($790) |
| 2025-06-12 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 200 | ₩6,000 | -82.6% | ₩1M ($833) |
| 2025-06-11 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 200 | ₩5,290 | -80.3% | ₩1M ($735) |
| 2025-06-10 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 300 | ₩4,600 | -77.3% | ₩1M ($958) |
| 2025-06-09 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 700 | ₩4,000 | -73.9% | ₩3M ($2K) |
| 2025-06-05 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 2.9K | ₩3,910 | -73.3% | ₩11M ($8K) |
| 2025-06-04 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 1.3K | ₩3,400 | -69.3% | ₩4M ($3K) |
| 2025-06-02 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 2.4K | ₩2,985 | -65.0% | ₩7M ($5K) |
| 2025-05-29 | BUY | 상속 | 이상현 Sanghyun Lee | CEO | 1.7K | ₩3,430 | -69.5% | ₩6M ($4K) |
| 2025-03-26 | BUY | 신규선임 | 황운봉 Hwangunbong Peak | moving | 31.5K | ₩4,400 | -76.3% | ₩139M ($96K) |
| 2021-07-30 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 8 | ₩20,900 | -95.0% | ₩167K ($116) |
| 2021-07-30 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 34 | ₩20,900 | -95.0% | ₩711K ($493) |
| 2021-07-30 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 85 | ₩20,900 | -95.0% | ₩2M ($1K) |
| 2021-07-30 | BUY | Market Buy | 이상현 Sanghyun Lee | CEO | 45 | ₩20,900 | -95.0% | ₩941K ($653) |
| 2021-07-27 | BUY | 무상신주취득 | 이상현 Sanghyun Lee | CEO | 1.3M | ₩21,600 | -95.2% | ₩27.5B ($19.1M) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Femtobiomed. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.